LUIS GONZAGA
PAZ-ARES RODRÍGUEZ
Profesor titular de universidad
Instituto de Biomedicina de Sevilla
Sevilla, EspañaPublicaciones en colaboración con investigadores/as de Instituto de Biomedicina de Sevilla (21)
2017
-
Safety Analyses of Pemetrexed-cisplatin and Pemetrexed Maintenance Therapies in Patients With Advanced Non-squamous NSCLC: Retrospective Analyses From 2 Phase III Studies
Clinical Lung Cancer, Vol. 18, Núm. 5, pp. 489-496
2016
-
IL-11 and CCL-1: Novel Protein Diagnostic Biomarkers of Lung Adenocarcinoma in Bronchoalveolar Lavage Fluid (BALF)
Journal of Thoracic Oncology, Vol. 11, Núm. 12, pp. 2183-2192
2015
-
Non-small-cell lung cancer: Role of the immune system and potential for immunotherapy
Journal of Thoracic Oncology, Vol. 10, Núm. 7, pp. 974-984
2014
-
Afatinib in the treatment of EGFR mutation-positive NSCLC - A network meta-analysis
Lung Cancer, Vol. 85, Núm. 2, pp. 230-238
-
Long-Term and Low-Grade Safety Results of a Phase III Study (PARAMOUNT): Maintenance Pemetrexed Plus Best Supportive Care Versus Placebo Plus Best Supportive Care Immediately after Induction Treatment with Pemetrexed Plus Cisplatin for Advanced Nonsquamous Non-Small-Cell Lung Cancer
Clinical Lung Cancer, Vol. 15, Núm. 6, pp. 418-425
-
Pooled analysis of clinical outcome for EGFR TKI-treated patients with EGFR mutation-positive NSCLC
Journal of Cellular and Molecular Medicine, Vol. 18, Núm. 8, pp. 1519-1539
-
VeriStrat: A prognostic and/or predictive biomarker for advanced lung cancer patients?
Expert Review of Respiratory Medicine, Vol. 8, Núm. 1, pp. 1-4
2013
-
Identification of oxidative stress related proteins as biomarkers for lung cancer and chronic obstructive pulmonary disease in bronchoalveolar lavage
International Journal of Molecular Sciences, Vol. 14, Núm. 2, pp. 3440-3455
-
Inhibidores de MET en el cáncer de pulmón
Revisiones en Cancer
-
Inhibition of HSP90 molecular chaperones: Moving into the clinic
The Lancet Oncology, Vol. 14, Núm. 9
-
Tratamiento de mantenimiento en el cáncer no microcítico de pulmón (CNMP)
Revisiones en Cancer
2012
-
Association between the miRNA signatures in plasma and bronchoalveolar fluid in respiratory pathologies
Disease Markers, Vol. 32, Núm. 4, pp. 221-230
-
Beyond first-line NSCLC therapy: Chemotherapy or erlotinib?
The Lancet Oncology
-
Complete longitudinal analyses of the randomized, placebo-controlled, phase III trial of sunitinib in patients with gastrointestinal stromal tumor following imatinib failure
Clinical Cancer Research, Vol. 18, Núm. 11, pp. 3170-3179
-
EGFR expression as a predictor of survival for first-line chemotherapy plus cetuximab in patients with advanced non-small-cell lung cancer: Analysis of data from the phase 3 FLEX study
The Lancet Oncology, Vol. 13, Núm. 1, pp. 33-42
-
Maintenance treatment of advanced non-small-cell lung cancer: Results of an International Expert Panel Meeting of the Italian Association of Thoracic Oncology
Lung Cancer, Vol. 76, Núm. 3, pp. 269-279
-
Trabectedin in pre-treated patients with advanced or metastatic soft tissue sarcoma: A phase II study evaluating co-treatment with dexamethasone
Investigational New Drugs, Vol. 30, Núm. 2, pp. 729-740
2011
-
Down-regulation of spinophilin in lung tumours contributes to tumourigenesis
Journal of Pathology, Vol. 225, Núm. 1, pp. 73-82
-
First-cycle rash and survival in patients with advanced non-small-cell lung cancer receiving cetuximab in combination with first-line chemotherapy: A subgroup analysis of data from the FLEX phase 3 study
The Lancet Oncology, Vol. 12, Núm. 1, pp. 30-37
-
Molecular biomarkers in non-small-cell lung cancer: a retrospective analysis of data from the phase 3 FLEX study
The Lancet Oncology, Vol. 12, Núm. 8, pp. 795-805